GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (NAS:IBRX) » Definitions » Beneish M-Score

IBRX (ImmunityBio) Beneish M-Score : 6.65 (As of Dec. 13, 2024)


View and export this data going back to 2021. Start your Free Trial

What is ImmunityBio Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 6.65 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for ImmunityBio's Beneish M-Score or its related term are showing as below:

IBRX' s Beneish M-Score Range Over the Past 10 Years
Min: -5.22   Med: -2.83   Max: 6.65
Current: 6.65

During the past 5 years, the highest Beneish M-Score of ImmunityBio was 6.65. The lowest was -5.22. And the median was -2.83.


ImmunityBio Beneish M-Score Historical Data

The historical data trend for ImmunityBio's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunityBio Beneish M-Score Chart

ImmunityBio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
- - -3.45 0.31 -2.50

ImmunityBio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.70 -2.50 -2.66 -3.01 6.65

Competitive Comparison of ImmunityBio's Beneish M-Score

For the Biotechnology subindustry, ImmunityBio's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ImmunityBio's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunityBio's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where ImmunityBio's Beneish M-Score falls into.



ImmunityBio Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of ImmunityBio for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.1599+0.528 * 1+0.404 * 1.0922+0.892 * 13.1871+0.115 * 0.9865
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.099+4.679 * -0.234981-0.327 * 1.1767
=6.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was $4.90 Mil.
Revenue was 6.106 + 1.047 + 0.04 + 0.139 = $7.33 Mil.
Gross Profit was 6.106 + 1.047 + 0.04 + 0.139 = $7.33 Mil.
Total Current Assets was $163.15 Mil.
Total Assets was $364.57 Mil.
Property, Plant and Equipment(Net PPE) was $174.23 Mil.
Depreciation, Depletion and Amortization(DDA) was $18.01 Mil.
Selling, General, & Admin. Expense(SGA) was $160.16 Mil.
Total Current Liabilities was $60.96 Mil.
Long-Term Debt & Capital Lease Obligation was $735.88 Mil.
Net Income was -85.729 + -134.564 + -134.109 + -233.392 = $-587.79 Mil.
Non Operating Income was 34.11 + 2.935 + -1.607 + -116.202 = $-80.76 Mil.
Cash Flow from Operations was -98.763 + -100.347 + -106.982 + -115.271 = $-421.36 Mil.
Total Receivables was $2.33 Mil.
Revenue was 0.082 + 0.041 + 0.36 + 0.073 = $0.56 Mil.
Gross Profit was 0.082 + 0.041 + 0.36 + 0.073 = $0.56 Mil.
Total Current Assets was $215.08 Mil.
Total Assets was $432.42 Mil.
Property, Plant and Equipment(Net PPE) was $187.81 Mil.
Depreciation, Depletion and Amortization(DDA) was $19.13 Mil.
Selling, General, & Admin. Expense(SGA) was $122.73 Mil.
Total Current Liabilities was $90.32 Mil.
Long-Term Debt & Capital Lease Obligation was $712.90 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(4.904 / 7.332) / (2.325 / 0.556)
=0.668849 / 4.181655
=0.1599

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.556 / 0.556) / (7.332 / 7.332)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (163.15 + 174.231) / 364.57) / (1 - (215.082 + 187.81) / 432.419)
=0.074578 / 0.068283
=1.0922

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=7.332 / 0.556
=13.1871

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(19.126 / (19.126 + 187.81)) / (18.012 / (18.012 + 174.231))
=0.092425 / 0.093694
=0.9865

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(160.162 / 7.332) / (122.725 / 0.556)
=21.844244 / 220.728417
=0.099

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((735.879 + 60.96) / 364.57) / ((712.903 + 90.324) / 432.419)
=2.185695 / 1.85752
=1.1767

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-587.794 - -80.764 - -421.363) / 364.57
=-0.234981

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

ImmunityBio has a M-score of 6.65 signals that the company is likely to be a manipulator.


ImmunityBio Beneish M-Score Related Terms

Thank you for viewing the detailed overview of ImmunityBio's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmunityBio Business Description

Traded in Other Exchanges
Address
3530 John Hopkins Court, San Diego, CA, USA, 92121
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
Executives
Patrick Soon-shiong director, 10 percent owner, officer: See remarks 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
California Capital Equity, Llc 10 percent owner 10182 CULVER BOULEVARD, CULVER CITY CA 90232
Nant Capital, Llc 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Cambridge Equities, Lp 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Mp 13 Ventures, Llc 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Michael D Blaszyk director C/O NANTKWEST, INC., 2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
John Owen Brennan director C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Wesley Clark director C/O ARGYLE SECURITY ACQUISITION CORP., 200 CONCORD PLAZA, SUITE 700, SAN ANTONIO TX 78216
Regan J Lauer officer: Chief Accounting Officer 4250 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA 92037
Richard Adcock officer: Chief Executive Officer C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Cheryl Cohen director C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Linda Maxwell director 1040 SPRING STREET, SILVER SPRING NC 27709
Christobel Selecky director C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
David C. Sachs officer: Chief Financial Officer C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Frederick W Driscoll director

ImmunityBio Headlines

From GuruFocus

NantKwest, Inc. - Special Call Transcript

By GuruFocus Research 02-07-2024